[1] Chinese Society of Hepatology, Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for chronic hepatitis B (2010 version) [J].J Clin Hepatol, 2011, 27 (1) :I-XVI. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010年版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI.
|
[2]WANG YJ, YANG L, ZUO JP.Recent developments in antivirals against hepatitis B virus[J].Virus Res, 2016, 213 (1) :205-213.
|
[3]KIM V, ABREU RM, NAKAGAWA DM, et al.Pegylated interferon alfa for chronic hepatitis B:systematic review and meta-analysis[J].J Viral Hepat, 2016, 23 (3) :154-169.
|
[4]ALIMUJIANG MLAS, BULIBULI MNF, GULIJIAZIYILA, et al.Effect of different therapeutic regimen in the treatment of HBe Agpositive chronic hepatitis B and the influence on the serum IFN-γand IL-10[J].China Med Herald, 2017, 14 (5) :137-140. (in Chinese) 阿力木江·毛拉艾沙, 布力布力·马那甫, 古丽加孜依拉, 等.不同用药方案治疗HBe Ag阳性慢性乙型肝炎的效果及对血清IFN-γ、IL-10的影响[J].中国医药导报, 2017, 14 (5) :137-140.
|
[5]PENG H, WEI F, LIU JY, et al.Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification:a meta-analysis[J].Hepatol Int, 2015, 9 (4) :543-557.
|
[6]PIRATVISUTH T, MARCELLIN P, POPESCU M, et al.Hepatitis B surface antigen:association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients[J].Hepatol Int, 2013, 7 (2) :429-436
|
[7]WANG YC, YANG SS, SU CW, et al.Predictors of response to pegylated interferon in chronic hepatitis B:a real-world hospitalbased analysis[J].Sci Rep, 2016, 6:29605.
|
[8]ZHANG HY, ZHOU P, GONG ZJ.Predictive value of HBs Ag quantification in pegylated interferon therapy for chronic hepatitis B[J].J Clin Hepatol, 2016, 32 (5) :977-980. (in Chinese) 张海月, 周培, 龚作炯.HBs Ag定量检测对聚乙二醇干扰素治疗慢性乙型肝炎效果的预测价值[J].临床肝胆病杂志, 2016, 32 (5) :977-980.
|
[9]ZHANG N, YAN XB, HAO JG, et al.Changes and clinical significance of quantitative hepatitis B surface antigen in patients with chronic hepatitis B receiving interferon therapy[J/CD].Chin J Exp Clin Infect Dis:Electronic Edition, 2016, 10 (2) :146-150. (in Chinese) 张楠, 颜学兵, 郝俊贵, 等.HBs Ag定量在慢性乙型肝炎患者干扰素抗病毒治疗中的变化及临床意义[J/CD].中华实验和临床感染病杂志:电子版, 2016, 10 (2) :146-150.
|
[10]SONNEVELD MJ, RIJCKBORST V, BOUCHER CA, et al.Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline[J].Hepatology, 2010, 52 (4) :1251-1257.
|
[11]YANG S, XING H, WANG Y, et al.HBs Ag and HBe Ag in the prediction of a clinical response to peginterferonα-2b therapy in Chinese HBe Ag-positive patients[J].Virol J, 2016, 13 (1) :180-188.
|
[12]LIN ZH, WANG BB, LIN XF, et al.Clinical efficacy and influencing factors of IFN-αtreatment on chronic hepatitis B[J].Chin J Biochem Pharmaceut, 2014, 34 (2) :99-100.
|